UK Regulators Approve Alzheimer’s Treatment Leqembi, But NHS Denies Reimbursement

The United Kingdom’s Medicines and Healthcare products Regulatory Agency recently gave the green light for lecanemab (Leqembi) as a treatment option for patients in the early stages of Alzheimer’s disease. However, the National Institute for Health and Care Excellence (NICE) in the UK has opted not to recommend reimbursement for the medication under the National Health Service (NHS).

According to a Telegraph report, a spokesperson for NICE highlighted concerns about the costs associated with providing the treatment, which includes regular hospital infusions and intensive monitoring for side effects. The relatively modest benefits observed in patients receiving Leqembi were deemed insufficient to justify the financial burden on the NHS. The draft guidance from NICE is now open for public consultation until September 20th before a final decision is made by the NHS.

Alzheimer’s Research UK representative, Ms. Evans-Newton, expressed optimism that ongoing price negotiations between NICE, drug manufacturer Eisai, and the NHS could lead to a potential resolution.

Comparisons can be drawn between NICE’s evaluation of Leqembi and the assessment conducted by the U.S. Institute for Clinical and Economic Review (ICER). In 2023, ICER’s independent committee concluded that the existing data did not sufficiently demonstrate a net health benefit for lecanemab compared to standard care. The analysis suggested that Leqembi could meet cost-effectiveness thresholds if priced between $8,900 and $21,500 per year, whereas the current price stands at $26,500 annually.

The uncertainty surrounding Leqembi’s market success is further compounded by the rejection of the medication by the European Medicines Agency over safety concerns. Despite its approval by the FDA in the U.S., challenges in Europe and the UK present obstacles to widespread adoption.

Leqembi’s mechanism of action involves targeting beta amyloid plaque in the brain, a protein believed to contribute to Alzheimer’s disease progression. Clinical trials have shown a modest improvement in cognitive decline for patients in the early stages of the disease, offering hope for those affected.

However, reports from the Financial Times indicate that Leqembi has not met initial sales projections in the U.S., with concerns raised by neurologists regarding the clinical significance of the drug’s effects on cognitive decline. Safety issues, including brain abnormalities and fatalities linked to the use of lecanemab, have also raised red flags among healthcare providers.

In conclusion, the balance between benefits and risks, coupled with the cost-effectiveness of Leqembi, poses challenges to its widespread adoption in healthcare systems. Ongoing discussions and negotiations may offer a path forward for patients seeking access to this innovative Alzheimer’s treatment.